,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Mr. Andr√©  Godin C.A., CPA, CA, CPA', 'age': 58, 'title': 'Pres & CFO', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 242066, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
1,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Mr. Tommy  Kenny J.D., L.L.B., M.Sc.', 'age': 35, 'title': 'Sr. VP & Gen. Counsel', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 141205, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
2,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Ms. Nadine  Paiement', 'age': 45, 'title': 'Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 151694, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
3,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Mr. Dwight  Gorham', 'title': 'Chief Exec. Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
4,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Stephen  Kilmer', 'title': 'Investor Relations Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
5,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Dr. David M. Kideckel M.B.A., MBA, Ph.D.', 'age': 41, 'title': 'Sr. VP and Head of Corp. Devel. & Strategic', 'yearBorn': 1981, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
6,6420 Abrams,Ville Saint Laurent,Montreal,QC,H4S 1Y2,Canada,514-331-7440,514-331-0436,https://www.intelgenx.com,Biotechnology,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.","{'maxAge': 1, 'name': 'Ms. Ingrid  Zerbe', 'age': 68, 'title': 'Corp. Sec.', 'yearBorn': 1954, 'fiscalYear': 2006, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.14105,0.14539,0.14,0.14539,0.14105,0.14539,0.14,0.14539,0.0,2.498962,1.1916667,25422,25422,53435,43830,43830,0.0,0.0,0,0,24976096,0.1,0.27,40.94442,0.16,0.17675,0.0,0.0,USD,37904108,0.0,130209358,174658000,0.23158,3.0000001e-05,-0.052,1672444800,1703980800,1688083200,-11208000,-0.06,0.12,62.138,-4.077,PNK,EQUITY,IGXT,IGXT,INTELGENX TECHNOLOGIES CORPORAT,IntelGenx Technologies Corp.,1169044200,America/New_York,EDT,-14400000,0.143,2.0,buy,1252000,0.007,-9296000,14180000,0.186,0.23,610000,0.003,-0.57176,-908000,-5521750,-9205000,-0.666,-1.97541,0.0,-16.50656,USD,
